![Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland, Join a Growing List of Provinces Providing Public Drug Plan Reimbursement for Teva Canada's AJOVY® (fremanezumab), for the Preventive Treatment of Migraine in Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland, Join a Growing List of Provinces Providing Public Drug Plan Reimbursement for Teva Canada's AJOVY® (fremanezumab), for the Preventive Treatment of Migraine in](https://smartcdn.gprod.postmedia.digital/financialpost/wp-content/uploads/2022/05/bw20220512006052_ajovy_box_2825_29.jpeg)
Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland, Join a Growing List of Provinces Providing Public Drug Plan Reimbursement for Teva Canada's AJOVY® (fremanezumab), for the Preventive Treatment of Migraine in
Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2022 American Headache Society Annual Meeting
![Teva launches AJOVY for the treatment of migraine with the YpsoMate autoinjector from Ypsomed - Ypsomed - Group Teva launches AJOVY for the treatment of migraine with the YpsoMate autoinjector from Ypsomed - Ypsomed - Group](https://www.ypsomed.com/files/media/02_Images/09_Press_Releases/Ajovy_Pen_CMYK_DE_ohneSchatten_low.png)
Teva launches AJOVY for the treatment of migraine with the YpsoMate autoinjector from Ypsomed - Ypsomed - Group
![Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2022 American Headache Society Annual Meeting | Business Wire Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2022 American Headache Society Annual Meeting | Business Wire](https://mms.businesswire.com/media/20220606005041/en/739014/23/teva_RGB_JPEG.jpg)